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Chest painAbstract Objective: To assess the value of using heart-type fatty acid-binding protein (H-FABP)
as a marker of acute myocardial infarction (AMI) in patients presenting with non-ST segment
elevation ACS (NSTE-ACS) in comparison with troponin-T (cTnT).
Methods: 122 consecutive patients presented with ischemic-type chest pain within the first 4 h of
symptom onset with NSTE-ACS. Blood samples were obtained on arrival for H-FABP and cTnT.
Patients with cTnT negative test on admission had a repeat analysis 6 h later. Patients with both
H-FABP negative and admission cTnT positive had repeat analysis of H-FABP 6 h later.
Results: On admission, H-FABP was positive in 84 patients (68.9%) versus 36 patients (29.5%)
with cTnT (p= 0.032). On repeat analysis after 6 h, total number of cTnT positive patients was
94 (77%) and cTnT negative was 28 (23%). All cTnT negative patients had negative H-FABP.
Of cTnT positive patients, 84 (89.4%) had positive H-FABP test while the remaining 10 (10.6%)
had ‘‘false” negative results.
Using the final results of cTnT positive as gold standard, early assessment of cTnT within 4 h of
chest pain had sensitivity of 38.3% and specificity of 100% while H-FABP had sensitivity of
89.4% and specificity of 100%.
Conclusions: For patients presenting with suspected ACS within 4 h of onset of symptoms,
H-FABP detects a significantly larger number of patients with NSTEMI compared to troponin-T.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Background
Chest pain accounts for a large proportion of adult emergency
room (ER) attendances and hence the ability to rapidly
identify ischemic chest pain is of importance.1,2 Acute
coronary syndromes (ACS), which include unstable angina
and myocardial infarction (MI) with or without ST-segment
elevation, are life-threatening disorders that remain a source of
12 A. El Missiri et al.high morbidity and mortality despite advances in treatment.3
Currently used biomarkers for cardiac ischemia are elevated
in blood plasma after a delay of several hours and therefore
unable to detect acute coronary syndrome (ACS) in a very
early stage.4
Cardiac troponin (cTn) and creatine kinase MB isoenzyme
(CK-MB) lack early sensitivity because their blood concentra-
tions do not increase appreciably until 4–6 h after the onset of
acute myocardial infarction (AMI), while most patients with
symptoms suggestive of ACS present themselves to the ER
between 1 and 3 h after onset of symptoms and optimal patient
outcomes for those with AMI rely on the timely and effective
implementation of proven therapies.5
Heart-type fatty acid-binding protein (H-FABP) is a novel
biochemical marker found to be released early into the blood
stream as early as 30 min after the onset of acute MI.6 It is a
small (15 kDa) cytoplasmic protein involved in lipid homeosta-
sis, abundant in heart muscle. It is approximately 10-fold
lower in skeletal muscle than in heart muscle, and the amounts
in the kidney, liver, and small intestine are even lower.7
H-FABP molecule is smaller than troponin and unbound
within the cell, allowing its release into the blood stream earlier
following restriction of oxygen to the heart.8
This study was done to assess the value of using H-FABP as
a marker of AMI in patients presenting with non-ST segment
elevation ACS (NSTE-ACS) in comparison with troponin-T.Venous sample for H-FAPB and Troponin-T 
H-FABP +ve








Figure 1 Sampling process for cardiac biomarkers.2. Methods
This study included 122 consecutive patients presented to Ain
Shams University hospitals with ischemic-type chest pain
within the first 4 h of symptom onset who were admitted with
the diagnosis of non-ST segment elevation acute coronary
syndrome (NSTE-ACS).
NSTE-ACS was defined according to the European Society
of Cardiology (ESC) and American College of Cardiology/
American Heart Association (ACC/AHA) guidelines as patients
with acute chest pain but without persistent ST-segment eleva-
tion or new onset left bundle branch block (LBBB) (i.e. having
rather persistent or transient ST-segment depression or
T-wave inversion, flat T waves, pseudo-normalization of
T waves, or no ECG changes at presentation) based on the
measurement of cardiac markers, they further qualify as
non-ST-elevation MI (NSTEMI) or unstable angina.9,10
Ischemic-type chest pain was defined as prolonged
(>20 min) anginal pain at rest; new onset angina (Class II
or III of the Classification of the Canadian Cardiovascular
Society (CCS))11; recent destabilization of previously stable
angina with at least CCS Class III angina characteristics; or
post-MI angina. Typical anginal pain was considered as
retrosternal pressure or heaviness radiating to the left arm,
neck, or jaw, which may be intermittent or persistent. It may
be accompanied by diaphoresis, nausea, abdominal pain,
dyspnea, and syncope.
Patients were excluded from the study, if they had chest
pain lasting more than 4 h before medical contact;
ST-segment elevation or new onset of LBBB on ECG; end
stage renal disease or renal impairment; or chronic liver
disease. Approval from institutional medical research ethical
committee was obtained and an informed consent was
obtained from all patients.Detailed history was taken from all patients with thorough
analysis of chest pain; time from pain to medical contact; risk
factors for developing coronary artery disease (CAD) (smoking
status, diabetes mellitus, hypertension, dyslipidemia, family
history of premature CAD in first-degree relatives); history of
renal disease (defined as end-stage renal disease on regular
dialysis, or serum creatinine level more than 1.5 mg/dL).
2.1. Cardiac biomarkers analysis
Venous blood samples were obtained from all patients (Fig. 1)
on arrival to the ER for heart-type fatty acid-binding protein
(H-FABP), troponin-T, and serum creatinine. Patients found
to have a troponin-T negative test on admission had a repeat
analysis from another sample withdrawn 6 h later. Patients
found to have both an H-FABP negative test and an admission
troponin-T positive test had a repeat analysis from another
sample withdrawn 6 h later for assessment of H-FABP to
assess whether H-FABP had failed to diagnose those patients
on admission or whether it was just delayed diagnosis.
2.2. Heart-type fatty acid-binding protein test
We used a rapid test card, qualitative, solid phase, two-site
sandwich immuno-chromatographic assay for the detection
of H-FABP in serum. Performing the test required extracting
the test card from the pouch, applying the blood sample to
the sample well then waiting for 15 min to obtain results.12
The membrane of the test card used was pre-coated with
capture anti-H-FABP antibodies on the test band region and
colloidal gold-labeled antibody on the control band region.
The reaction was initiated by adding 100–120 lL of venous
blood to the well with heparin used as an anticoagulant. The
test result was considered positive when two red lines (control
and result) were visible indicating that the concentration of
H-FABP in the sample was above the threshold value of
7 lg/L. The test result was considered negative when only one
red line was visible at control indicating that the concentration
of H-FABP was equal to or below the threshold value. The test
was considered invalid and discarded and immediately repeated
if no lines were visible or if a line was visible only at result.13
The result of each test was confirmed by both the ER physician
and cardiologist on call.
2.3. Troponin-T assessment
Qualitative assessment was done using a one-step troponin-T
test card device with membrane based immunoassay for the
Table 1 Baseline patient characteristics.
Number 122
Age (years) 54.6 ± 9.8
Male gender, n (%) 96 (78.7%)
Diabetes mellitus (type II), n (%) 76 (62.3%)
Hypertension, n (%) 80 (65.6%)
Current Smoker, n (%) 74 (60.7%)
Dyslipidemia, n (%) 62 (50.8%)
Family history of premature CAD, n (%) 52 (42.6%)
Time from onset of chest pain to medical contact
(minutes)
187.2 ± 48
Admission ECG, n (%)
–Normal 22 (18%)
–ST-segment changes 46 (37.7%)
–T-wave changes 34 (27.9%)
–Pathological Q waves 20 (16.4%)
Continuous variables are expressed as mean and standard
deviation, whereas categorical variables are expressed as numbers
(percentage).
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Figure 2 Comparing number of patients with troponin-T and
H-FABP positive results on admission and after 6 h.
Novel cardiac biomarker 13detection of cTnT. The membrane of the test used was pre-
coated with capture reagent on the test line region of the test
card. During testing, the whole blood specimen reacted with
the particle coated with anti-cTnT antibodies. The presence
of a colored line in the test line region indicated a positive
result, while its absence indicated a negative result. To serve
as a procedural control, a colored line must always have
appeared in the control line region. If the control line did
not appear, the test result was considered invalid and was
immediately repeated. The result of each test was confirmed
by both the ER physician and cardiologist on call.
2.4. Statistical analysis
Data were statistically analyzed using SPSS statistical package
version 17 (SPSS Inc., Chicago, IL, USA). Categorical
variables were expressed as number and percentage. Continuous
variables were expressed as mean ± SD. Tests used were
Student’s t-test for continuous variables and chi-square test
or Fisher’s exact test when the expected count was less than
5 for categorical variables. Correlations were done usingPearson’s correlation coefficient. A probability value
p< 0.05 was considered statistically significant and a p
value < 0.0001 was considered highly significant.
3. Results
3.1. Baseline characteristics
This study included 122 consecutive patients in the period
from March 2014 to January 2015. The mean patient age
was 54.6 ± 9.8 years with 96 males (78.7%). Seventy-six
patients (62.3%) had diabetes mellitus (all type II), 80 patients
(65.6%) were hypertensive, 74 patients (60.7%) were current
smokers, 62 patients (50.8%) had dyslipidemia, and 52
patients (42.6%) had a positive history of premature CAD.
The time from onset of chest pain to medical contact ranged
from 45 to 240 min with an average of 187.2 ± 48 min.
Admission ECG was normal in 22 patients (18%), 46
patients (37.7%) had significant ST-segment depression, 34
patients (27.9%) had T-wave changes, and 20 patients
(16.4%) had pathological Q waves of old myocardial infarction
(Table 1).
3.2. Cardiac biomarkers on admission
A larger number of patients had H-FABP positive on admis-
sion 84 patients (68.9%) versus 36 patients (29.5%) with cTnT
(p= 0.032). Of the H-FABP positive patients 30 (35.7%) had
admission cTnT test positive while 54 (64.3%) had a negative
test (Fig. 2).
3.3. Repeat analysis for admission troponin-T negative patients
The 86 patients (70.5%) with a cTnT negative test on admis-
sion had a second assessment after 6 h. Of them 58 patients
(67.4%) had cTnT positive results on repeat testing and 28
patients (32.6%) still had negative results.
On examining results of the repeat troponin-T test with the
admission H-FABP test results, we found that of the 58
patients with repeat cTnT positive test 54 patients (93.1%)
had a positive admission H-FABP test, while the 28 patients
with negative repeat cTnT test all (100%) had negative
admission H-FABP test.
3.4. Comparing biomarkers at 6 h from admission for all patients
After repeat testing 6 h from admission, the total number of
cTnT positive patients was 94 (77%) and that with cTnT
negative was 28 (23%). All troponin-T negative patients had
negative H-FABP results. Of the troponin-T positive patients,
84 (89.4%) had positive H-FABP test while the remaining 10
(10.6%) had ‘‘false” negative results (H-FABP negative and
cTnT positive). For those with false negative results, we did
a repeat assessment of H-FABP after 6 h and found 4 patients
to have a positive result while 6 patients had the same negative
results.
So the final total number of H-FABP positive patients was
88 (72.1%) and that with H-FAPB negative was 34 (27.9%)
(Fig. 2).
Table 2 Sensitivity and specificity of H-FABP and admission










Ruzgar et al.21 95.2 100 38.1 100
Cavus et al.22 97.6 88.5 100 88.5
Figiel et al.23 94.7 100 64.9 100
Body et al.8 75 89 42 96
Naroo et al.24 75.8 97 58.6 98.8
Gururajan
et al.25
92 93 54 95
Xie et al.26 81.8 100 40.9 100
This study 89.4 100 38.3 100
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pain onset
Using the final results of cTnT positive patients after 6 h from
admission as the gold standard, we found that early assessment
of cTnT within 4 h of chest pain onset had a sensitivity of
38.3%, a specificity of 100%, a positive predictive value of
100%, and a negative predictive value of 32.5%.
3.6. Sensitivity and specificity of H-FABP
Using the final results of cTnT positive patients after 6 h from
admission as the gold standard, we found that H-FABP within
4 h of chest pain onset had a sensitivity of 89.4%, a specificity
of 100%, a positive predictive value of 100%, a negative
predictive value of 73.7%, and an accuracy of 91.8%.
4. Discussion
The burden of acute coronary syndromes is increasing expo-
nentially, making the rapid and accurate diagnosis of utmost
importance.14,15 Early diagnosis of NSTEMI leads to a reduc-
tion of morbidity and mortality in such patients as the patients
will be risk stratified sooner, hence receiving the necessary
pharmacological and/or interventional management in a
timely manner.16
Having point-of-care tests available such as troponin-T
readily available in the ER helps to identify such patients
who are at increased risk of major adverse cardiac events.
Despite the exhaustive evidence on the value of cTn in early
detection of myocardial damage to the point that it is an inte-
gral recommendation of all guidelines of practice for acute
coronary syndromes,9,10 the short time from onset of ischemic
chest pain till the rise of cTn has been proven valuable and
there is increasing demand for novel biomarkers that may be
able to detect myocardial damage at an earlier stage.
Human-type fatty acid-binding protein (H-FABP) has
shown promise in several studies and has been proven to detect
myocardial damage as early as 30 min after the onset of
ischemic chest pain reaching a peak in 6 h and returning to
normal within 24 h.12 This rapid return to number is valuable
in the detection of re-infarction.17
This study has demonstrated that a significantly larger
number of patients were detected by point-of-care H-FABP
test available in the ER compared to cTnT for patients pre-
senting in the very early hours (less than 4 h) after the onset
of chest pain and accordingly it can be used to rapidly rule
out acute myocardial infarction especially in those presenting
early after the onset of chest pain. We have also demonstrated
that point-of-care H-FABP test has a high sensitivity and
specificity when used in the first 4 h after symptom onset.
Other studies have shown that H-FABP improves the
diagnostic performance when combined with other cardiac
markers18,19 and that it is more sensitive than Troponin I
within 6 h of chest pain.20
4.1. H-FABP in other studies
We performed a comparison between sensitivity and specificity
of H-FABP and cTnT at presentation in patients in the currentstudy and several other studies (Table 2). Ruzgar et al. studied
40 consecutive patients presenting with suspected ACS; they
were divided into two groups; the first group (n= 26) seen
within 6 h of onset of chest pain and the other (n= 14) seen
within 6–24 h. They concluded that within 6 h of ACS,
H-FABP is a more sensitive biochemical marker than
troponin-T in the early detection of ischemic myocardial
necrosis; but after that the sensitivity of H-FABP decreases,
and it should not be used alone in patients admitted 24 h after
the onset of chest pain.21 Cavus et al. compared the efficacy of
H-FABP compared to CK-MB and troponin-T in early diag-
nosis of ACS in 67 patients presenting less than 1 h after onset
of chest pain. They examined the biomarkers at 4 h from
admission and concluded that point-of-care assays of
H-FABP in patients presenting within 20 h of symptom onset
may lead to an earlier diagnosis of ACS.22
Figiel and his colleagues studied 100 patients admitted with
chest pain lasting less than 24 h from admission and strong
suspicion of NSTE-ACS and measured H-FABP, troponin-
T, and CK-MB on admission, at 3 and 6 h. Data from admis-
sion results are shown in Table 2, and they also showed that
the positive predictive values were 100%, 92.6% and 100%
and the negative predictive values were 93.4%, 67.8% and
68.2% for H-FABP, CK-MB and troponin-T respectively.23
Another study assessing the value of early measurement of
H-FABP, CK-MB, and troponin-I examined 705 patients pre-
sented with ACS without persistent ST-segment elevation with
onset of chest pain less than 24 h. They concluded after evalu-
ating eight biomarkers for their potential to rapidly exclude
AMI at the time of presentation that while none of the
biomarkers alone were able to exclude AMI, multivariate
analysis identified that the optimal multi-marker strategy
incorporated H-FABP and troponin-I. Combined with clinical
risk stratification, this strategy could rapidly exclude AMI in
44.7% of all patients and suggested that H-FABP may play
an important role for enabling rapid exclusion of AMI in the
emergency room.8 Further results from other studies are
shown in Table 2.24–26
4.2. Use of novel biomarkers in practice
Although this was not examined in the current study, it is of
note that studies have shown the prognostic value of elevated
H-FABP in predicting long-term mortality and re-infarction in
Novel cardiac biomarker 15troponin-negative patients with acute coronary syndrome27 as
well as identifying high-risk patients.28 Other studies have
shown H-FABP only to improve diagnostic accuracy while
not adding any diagnostic value when high sensitivity
troponin-T is available.29,30 It is therefore generally recom-
mended to combine H-FABP to cTn which is more specific
to confirm or exclude AMI.
According to recent ACC/AHA guidelines for the manage-
ment of patients with NSTE-ACS, the use of selected newer
biomarkers may be reasonable to provide additional prognos-
tic information for patients with NSTE-ACS (Class IIb, level
of evidence: B).9 Similarly, ESC guidelines for the management
of ACS in patients presenting without persistent ST-segment
elevation state that early diagnosis of ACS may be improved
by measurements of fatty acid-binding protein.10
4.3. Study limitations
Limitations of the current study are that it comes from a single
medical center with a relatively limited number of patients. We
relied mainly on qualitative results as we meant to examine
point-of-care tests. Comparing to quantitative high sensitivity
troponin might be of added value but we aimed to assess point-
of-care tests. Follow-up of patients to show whether those
detected and managed early by the H-FABP test had better
outcomes in comparison with those detected later by
troponin-T was not done so we cannot identify the actual
effect on mortality and morbidity. Finally, the use of cardiac
Troponin-T as the gold standard to identify non-ST segment
elevation myocardial infarction might not have been appropri-
ate and it could have been more appropriate to use coronary
angiography; however, this was not feasible in our study due
to logistic and financial considerations.
5. Conclusion
For patients presenting with suspected ACS within 4 h of onset
of symptoms, H-FABP detects a significantly larger number of
patients with NSTEMI compared to troponin-T. Qualitative
H-FABP test has good sensitivity and specificity and thus
plays an important role in diagnosing or ruling out NSTEMI
in the emergency room.Conflict of interest
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